(E)-5-styryl-1,3,4-oxathiazol-2-one | 329206-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-5-styryl-1,3,4-oxathiazol-2-one
• 英文别名: 5-styryl-1,3,4-oxathiazol-2-one；5-[(E)-styryl]-1,3,4-oxathiazol-2-one；5-[(E)-2-phenylethenyl]-1,3,4-oxathiazol-2-one
• CAS: 329206-42-0
• 化学式: C₁₀H₇NO₂S
• 分子量: 205.237
• InChiKey: OZBLBNDLIBOLLG-VOTSOKGWSA-N

物化性质

• 沸点：
  320.4±35.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-5-styryl-1,3,4-oxathiazol-2-one 250.0 ℃ 、1.33 kPa 条件下， 反应 0.33h， 生成 邻四氯苯醌
  参考文献：
  名称：

  Sidky, M. M.; Mahran, M. R.; Abdou, W. M., Phosphorus and Sulfur and the Related Elements, 1983, vol. 15, p. 129 - 136

  摘要：

  DOI：
• 作为产物：
  描述：

  反-肉桂酰胺 、 氯羰基亚磺酰氯 以 四氢呋喃 为溶剂， 以40%的产率得到(E)-5-styryl-1,3,4-oxathiazol-2-one
  参考文献：
  名称：

  作为潜在的抗结核药物的5-苯乙烯基-氧杂噻唑-2-酮结核分枝杆菌蛋白酶体抑制剂的优化和评价。

  摘要：

  这是5-苯乙烯基草并恶唑-2-酮类药物作为结核分枝杆菌（Mtb）蛋白酶体抑制剂的首次报道。作为研究的一部分，已研究了草硫唑酮作为Mtb蛋白酶体抑制剂的构效关系。此外，与人蛋白酶体相比，制备的化合物对Mtb表现出良好的选择性。鉴定出的5-styryl-oxathiazol-2-one抑制剂对复制Mtb几乎没有活性，但对非复制细菌具有快速杀菌作用。（E）‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4 ‐‐‐‐‐‐‐‐yré‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ was ‐‐‐‐‐‐‐‐‐‐一was- ‐‐‐‐‐‐‐‐‐‐‐‐ 4？-‐‐‐‐‐‐‐‐‐‐‐‐‐‐5å？-‐‐‐‐‐‐‐‐‐‐‐‐ was？-‐‐‐‐‐‐‐‐‐‐‐‐waså？-‐‐‐ 5-（4-Chlorostyryl）‐1,3,4-Oxathiazol−2-1？的效果最佳，在所有测试浓度下的集落形成单位（CFU）/ mL仅在小于

  DOI：

  10.1002/open.201500001

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：MERCK & CO INC

  公开号：WO2001016121A1

  公开（公告）日：2001-03-08

  In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. At a ring position adjacent to a ring nitrogen atom, the heterocyclic ring has at least one substituent which includes a moiety, linked to the heterocyclic ring via an alkylene moiety, an alkynylene moiety or an azo group. Invention compounds are capable of a wide variety of uses including modulating physiological processes by functioning as agonists and antagonists of receptors in the nervous system, as insecticides, and as fungicides. The invention further provides methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds including the novel compounds referred to above. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of the above-described heterocyclic compounds.

  根据本发明，提供了一类新型的杂环化合物及其使用方法。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。在靠近环氮原子的环位置上，杂环环有至少一个取代基，包括一个官能团，通过烷基官能团、炔基官能团或偶氮基团连接到杂环环上。发明的化合物能够广泛应用，包括通过作为神经系统受体的激动剂和拮抗剂来调节生理过程，作为杀虫剂和杀菌剂。本发明还提供了使用特定定义的杂环化合物类来调节兴奋性氨基酸受体活性的方法，包括上述新型化合物。在一种实施例中，提供了调节代谢性谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。本发明还揭示了预防与肺系统疾病、神经系统疾病、心血管系统疾病、胃肠系统疾病、内分泌系统疾病、外分泌系统疾病、皮肤疾病、癌症和眼科系统疾病相关的疾病状态的方法。本发明还揭示了上述杂环化合物的药物可接受的盐形式。
• Methods of modulating processes mediated by excitatory amino acid receptors
  申请人：Cosford Nicholas D. P.

  公开号：US06956049B1

  公开（公告）日：2005-10-18

  In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.

  根据本发明，提供了使用一类特定定义的杂环化合物来调节兴奋性氨基酸受体活性的方法。在一种实施例中，提供了调节代谢型谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。所考虑的疾病包括脑缺血、慢性神经退行性疾病、精神障碍、精神分裂症、情绪障碍、运动功能外围疾病、肥胖症、呼吸、运动控制和功能障碍、注意力缺陷障碍、注意力障碍、疼痛障碍、神经退行性疾病、癫痫、惊厥性障碍、进食障碍、睡眠障碍、性障碍、昼夜节律障碍、药物戒断、药物成瘾、强迫障碍、焦虑、恐慌障碍、抑郁障碍、皮肤疾病、视网膜缺血、视网膜退化、青光眼、与器官移植相关的疾病、哮喘、缺血和星形细胞瘤。本发明还揭示了杂环化合物的药物可接受的盐形式的方法。
• Synthesis and crystal structures of halogenated oxathiazolones and an unexpected propanamide
  作者：Tanner George、Samantha W. McWilliams、Jason D. Masuda、Melbourne J. Schriver

  DOI：10.1107/s2053229623002152

  日期：2023.4.1

  The known 1,3,4-oxathiazol-2-ones with crystal structures reported in the Cambridge Structural Database are limited (13 to date) and this article expands the library to 15. In addition, convenient starting materials for the future exploration of 1,3,4-oxathiazol-2-ones are detailed. An unexpected halogenated propanamide has also been identified as a by-product of one reaction, presumably reacting with

  剑桥结构数据库中已知的具有晶体结构的 1,3,4-oxathiazol-2-ones 是有限的（迄今为止 13 个），本文将库扩展到 15 个。此外，为未来探索 1 提供了方便的起始材料,3,4-oxathiazol-2-ones 详述。一种意想不到的卤化丙酰胺也被确定为一个反应的副产物，可能与原位生成的 HCl 反应。5-[( E )-2-chloroethenyl]-1,3,4-oxathiazol-2-one, C 4 H 2 ClNO 2 S, ( 1 )的空间群为P 2 1，具有高Z ′值为 6；rac空间群-2,3-二溴-3-氯丙酰胺，C 3 H 4 Br 2 ClNO，( 2 )，为P 2 1，Z ′ = 4；和rac -5-(1,2-dibromo-2-phenylethyl)-1,3,4-oxathiazol-2-one的结构，C 10 H 7 Br 2 NO 2 S, (
• Paton, R. Michael; Stobie, Ian; Mortier, Roy M., Phosphorus and Sulfur and the Related Elements, 1983, vol. 15, p. 137 - 142
  作者：Paton, R. Michael、Stobie, Ian、Mortier, Roy M.

  DOI：——

  日期：——
• PATON, R. M.;STOBIE, I.;MORTIER, R. M., PHOSPH. AND SULFUR, 1983, 15, N 2, 137-142
  作者：PATON, R. M.、STOBIE, I.、MORTIER, R. M.

  DOI：——

  日期：——